Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE+ long-term safety and efficacy of efgartigimod IV in adult primary immune thrombocytopenia
jRCT2080225021Phase 3Completed
- Sponsor
- argenx
- Start
- Jan 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Started Jan 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2080225021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225021.